Lumicell highlighted clinical results presented at the recent Society of Surgical Oncology (SSO) in Atlanta, GA, that it says demonstrate the benefits of its Lumisight optical imaging agent for breast cancer.
In 2023, the company submitted a new drug application (NDA) for Lumisight for use in patients with breast cancer undergoing a lumpectomy, along with a premarket approval (PMA) application for its Direct Visualization System (DVS). On March 5, the U.S. Food and Drug Administration's (FDA) Medical Imaging Drugs Advisory Committee (MIDAC) voted in support of Lumisight's benefit-risk profile, according to the firm.
